Michael A. Metzger - Oct 6, 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Executive Officer, Director
Signature
/s/ Michael A. Metzger
Stock symbol
SNDX
Transactions as of
Oct 6, 2022
Transactions value $
-$268,162
Form type
4
Date filed
10/7/2022, 04:05 PM
Previous filing
Oct 4, 2022
Next filing
Nov 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $142K +16.2K +91.91% $8.77 33.9K Oct 6, 2022 Direct
transaction SNDX Common Stock Sale -$411K -16.2K -47.89% $25.29 17.7K Oct 6, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -16.2K -100% $0.00* 0 Oct 6, 2022 Common Stock 16.2K $8.77 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 674,528 options to purchase shares of common stock that are vested and immediately exercisable and a total of 485,001 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $25.1500 to $25.4350.
F3 This option is fully vested.